Industries > Pharma > Next-Generation Biologics Market 2018-2028

Next-Generation Biologics Market 2018-2028

Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

PUBLISHED: 12 March 2018
PAGES: 262
PRODUCT CODE: PHA0294

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

Next Generation Biologics Market Report 2018-2028: Forecasts by Market and Segments
• Do you need definitive Next Generation Biologics market data?
• Do you want to understand clear demarcation between next generation biologics and traditional biologics?
• Next Generation Biologics and sub-segment market analysis?
• Key drivers and constrains accompanied by this market?
• Clear leaders and lagers?
• Next wave of blockbusters and drivers impacting them?

Read on to discover how this definitive report can transform your own research and save you time.
The introduction of new pipeline drugs in Next generation biologics, has led visiongain to publish this timey report. The Next generation biologics market is expected to flourish in the next few years because of emergence of new phase III as well as marketed candidates which are going change the course of the market. Not only new candidates, but the technology (drug delivery as well as the mechanism of action) are novel which make the report a worth find and insightful.

Next-Generation Biologics Market 2018-2028

Report highlights

• 140 quantitative tables, charts, and graphs

• Analysis of key players in Next generation biologics Market
• Abbvie
• Roche/ Genentech
• Amgen
• GSK
• Eli Lilly
• Sanofi Aventis
• Novo Nordisk
• Seattle Genetics

• Global next generation biologics market outlook and analysis from 2018-2028

• Regional Next generation biologics market forecasts from 2018-2028
• US forecast 2018-2028,
• Japan forecast 2018-2028
• India forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• China forecast 2018-2028

• Key questions answered
• What does the future hold for the next generation biologics?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

• Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Next-Generation Biologics Market 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Next-Generation Biologics Market 2018-2028


Latest Pharma news

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

READ

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

READ

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

READ

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

READ

Categories

Category